Article Text

Download PDFPDF

OP0349 Remaining pain and widespread pain distribution during the first 12 months after ra diagnosis
  1. Y.C. Lee1,
  2. O. Schieir2,
  3. M.-F. Valois3,
  4. S.J. Bartlett3,
  5. G. Boire4,
  6. B. Haraoui5,
  7. C. Hitchon6,
  8. E. Keystone7,
  9. D. Tin8,
  10. C. Thorne9,
  11. J. Pope10,
  12. V. Bykerk7,11,
  13. on behalf of CATCH
  1. 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA
  2. 2University of Toronto Dalla Lana School of Public Health, Toronto
  3. 3McGill University, Montreal
  4. 4Universite De Sherbrooke, Sherbrooke
  5. 5Institut de Rheumatologie de Montreal, Montreal
  6. 6University of Manitoba, Winnipeg
  7. 7University of Toronto, Toronto
  8. 8Southlake Regional Health Center, Newmark
  9. 9Southlake Regional Health Center, Newmarket
  10. 10Western University, London, Canada
  11. 11Hospital for Special Surgery, New York, NY, USA


Background The incidence of fibromyalgia (FM), a chronic widespread pain syndrome, is highest in the first year after RA diagnosis.1 These 12 months may represent a critical window during which acute inflammatory pain transitions to chronic non-inflammatory pain. To prevent this transition, more data are needed about the course and predictors of pain during this time.

Objectives 1) To describe the evolution of pain during the 12 months after RA diagnosis, and 2) to identify predictors of remaining pain and widespread pain (previously described as ‘fibromyalgic RA’)2 at 12 months.

Methods Data were obtained from early RA patients in the Canadian Early Arthritis Cohort (CATCH), a prospective inception cohort. Primary outcomes were: 1) remaining pain above the Patient Acceptable Symptom State (PASS), defined as 4/10 on a pain intensity numerical rating scale,3 and 2) widespread pain, defined by tender joint count (TJC28) – swollen joint count (SJC28) ≥7.2 Descriptive statistics were used to summarise the frequency of remaining pain and widespread pain over 12 months. Logistic regression models were used to identify predictors of remaining pain and widespread pain at 12 months. Variables forced into the multivariable models included age, sex, SJC28, ESR, depression, back pain, OA, sleep problems, HAQ-disability index (DI), MTX use, non-MTX conventional synthetic DMARD (csDMARD) use and NSAID use. Additional variables considered for inclusion via a backward selection process were race, education, income, FM, number of comorbidities and steroid use. Both models were adjusted for their respective baseline values.

Results 1270 patients were included, with mean (SD) age of 53.9 (14.5) years, symptom duration of 5.8 (3.0) months and baseline DAS28 of 5.0 (1.4). The percentage of patients with remaining pain decreased from 64% at baseline to 24% at 12 months. The percentage of patients with widespread pain decreased from 9% to 5%. The strongest predictors of 12 month remaining pain were sleep problems (highest quartile OR 2.2, 95% CI: 1.2 to 3.9), pain intensity >4/10 (OR 2.1, 95% CI: 1.3 to 3.4) and higher HAQ-DI score (OR 1.5, 95% CI: 1.1 to 2.0). The strongest predictors of 12 month widespread pain were higher HAQ-DI score (OR 1.8, 95% CI: 1.1 to 3.1) and higher number of comorbidities (OR 1.2, 95% CI: 1.0 to 1.5). Baseline non-MTX csDMARD use was associated with lower likelihood of widespread pain (OR 0.5, 95% CI: 0.3 to 0.8).

Abstract OP0349 – Table 1

Multivariable logistic regression models for the association between baseline characteristics and a) remaining pain (pain NRS>4), and b) widespread pain distribution (TJC28-SJC28≥7)

Conclusions Despite improvements in pain during the first year after RA diagnosis, 24% continued to report remaining pain above the PASS, and 5% reported widespread pain at 12 months. Patients at greatest risk for 12 month remaining pain were those with sleep problems, severe pain and disability at baseline. Patients at greatest risk for widespread pain were those with high baseline disability and many comorbidities. Baseline inflammation was not associated with 12 month pain outcomes.

References [1] Lee YC, et al. Ann Rheum Dis2013;72:649–54.

[2] Pollard LC, et al. Rheumatology2010;49:924–8.

[3] Tubach F, et al. Arthritis Care Res2012;64:1699–707.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.